Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases

Khalid Hussain Al-Qahtani,1 Mushabbab Al Asiri,2 Mutahir A Tunio,2 Naji J Aljohani,3 Yasser Bayoumi,4 Iqbal Munir,5 Ayman AlAyoubi6 1Department of Otolaryngology – Head and Neck Surgery, College of Medicine, Advanced Head and Neck Oncology, King Saud University, 2Radiation Oncol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Al-Qahtani KH, Al Asiri M, Tunio MA, Aljohani NJ, Bayoumi Y, Munir I, AlAyoubi A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8706cb97a0ae4f0590928db5b1b1dd1e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8706cb97a0ae4f0590928db5b1b1dd1e
record_format	dspace
spelling	oai:doaj.org-article:8706cb97a0ae4f0590928db5b1b1dd1e2021-12-02T08:46:40ZNasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases1177-5483https://doaj.org/article/8706cb97a0ae4f0590928db5b1b1dd1e2014-12-01T00:00:00Zhttp://www.dovepress.com/nasolacrimal-duct-obstruction-following-radioactive-iodine-131-therapy-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Khalid Hussain Al-Qahtani,1 Mushabbab Al Asiri,2 Mutahir A Tunio,2 Naji J Aljohani,3 Yasser Bayoumi,4 Iqbal Munir,5 Ayman AlAyoubi6 1Department of Otolaryngology – Head and Neck Surgery, College of Medicine, Advanced Head and Neck Oncology, King Saud University, 2Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, 3Endocrinology and Thyroid Oncology, King Fahad Medical City, Riyadh, Saudi Arabia; 4Radiation Oncology, NCI, Cairo University, Cairo, Egypt; 5Nuclear Medicine Sulaiman Al-Habib Hospital, 6Clinical Ophthalmology, King Fahad Medical City, Riyadh, Saudi Arabia Background: Radioactive iodine 131 (131I) therapy has long been used in the treatment of differentiated thyroid cancers (DTC). While salivary and lacrimal glandular complications secondary to 131I therapy are well documented, there is little in the literature addressing nasolacrimal duct obstruction (NLDO). We aimed to evaluate the frequency of 131I therapy-acquired NLDO, its correlation to 131I therapy doses, and the surgical treatment outcome of this rare side effect.Methods: From 2000–2012, a retrospective review of 864 among 1,192 patients with confirmed DTC who were treated with 131I therapy was performed to examine the frequency of NLDO, its causative factors, as well as imaging, surgical intervention, and outcomes.Results: Nineteen (2.2%) patients were identified with NLDO. The mean age was 51.9±10.5 years (range: 39–72 years). Fifteen (78.9%) were female and four were male (21.1%). The mean individual 131I doses were 311.1±169.3 millicurie (mCi) (range: 150–600 mCi). The mean duration between the date of 131I therapy and the occurrence of NLDO was 11.6±4.1 months (range: 6.5–20). Fourteen (73.7%) patients had bilateral epiphora. Computed tomography dacryography allowed for the detection of all NLDO. Eighteen (94.7%) patients underwent dacryocystorhinostomy. Complete recovery was obtained in 14 (73.7%) patients. Age >45 years and 131I therapy doses >150 mCi were significantly correlated with NLDO (P=0.02 and P=0.03, respectively).Conclusion: NLDO is an underestimated complication of 131I therapy in DTC patients. Clinicians should be aware of this rare complication for prompt intervention. Keywords: nasolacrimal duct obstruction, radioactive iodine 131 therapy, differentiated thyroid cancersAl-Qahtani KHAl Asiri MTunio MAAljohani NJBayoumi YMunir IAlAyoubi ADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 2479-2484 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Al-Qahtani KH Al Asiri M Tunio MA Aljohani NJ Bayoumi Y Munir I AlAyoubi A Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases
description	Khalid Hussain Al-Qahtani,1 Mushabbab Al Asiri,2 Mutahir A Tunio,2 Naji J Aljohani,3 Yasser Bayoumi,4 Iqbal Munir,5 Ayman AlAyoubi6 1Department of Otolaryngology – Head and Neck Surgery, College of Medicine, Advanced Head and Neck Oncology, King Saud University, 2Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, 3Endocrinology and Thyroid Oncology, King Fahad Medical City, Riyadh, Saudi Arabia; 4Radiation Oncology, NCI, Cairo University, Cairo, Egypt; 5Nuclear Medicine Sulaiman Al-Habib Hospital, 6Clinical Ophthalmology, King Fahad Medical City, Riyadh, Saudi Arabia Background: Radioactive iodine 131 (131I) therapy has long been used in the treatment of differentiated thyroid cancers (DTC). While salivary and lacrimal glandular complications secondary to 131I therapy are well documented, there is little in the literature addressing nasolacrimal duct obstruction (NLDO). We aimed to evaluate the frequency of 131I therapy-acquired NLDO, its correlation to 131I therapy doses, and the surgical treatment outcome of this rare side effect.Methods: From 2000–2012, a retrospective review of 864 among 1,192 patients with confirmed DTC who were treated with 131I therapy was performed to examine the frequency of NLDO, its causative factors, as well as imaging, surgical intervention, and outcomes.Results: Nineteen (2.2%) patients were identified with NLDO. The mean age was 51.9±10.5 years (range: 39–72 years). Fifteen (78.9%) were female and four were male (21.1%). The mean individual 131I doses were 311.1±169.3 millicurie (mCi) (range: 150–600 mCi). The mean duration between the date of 131I therapy and the occurrence of NLDO was 11.6±4.1 months (range: 6.5–20). Fourteen (73.7%) patients had bilateral epiphora. Computed tomography dacryography allowed for the detection of all NLDO. Eighteen (94.7%) patients underwent dacryocystorhinostomy. Complete recovery was obtained in 14 (73.7%) patients. Age >45 years and 131I therapy doses >150 mCi were significantly correlated with NLDO (P=0.02 and P=0.03, respectively).Conclusion: NLDO is an underestimated complication of 131I therapy in DTC patients. Clinicians should be aware of this rare complication for prompt intervention. Keywords: nasolacrimal duct obstruction, radioactive iodine 131 therapy, differentiated thyroid cancers
format	article
author	Al-Qahtani KH Al Asiri M Tunio MA Aljohani NJ Bayoumi Y Munir I AlAyoubi A
author_facet	Al-Qahtani KH Al Asiri M Tunio MA Aljohani NJ Bayoumi Y Munir I AlAyoubi A
author_sort	Al-Qahtani KH
title	Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases
title_short	Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases
title_full	Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases
title_fullStr	Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases
title_full_unstemmed	Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases
title_sort	nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/8706cb97a0ae4f0590928db5b1b1dd1e
work_keys_str_mv	AT alqahtanikh nasolacrimalductobstructionfollowingradioactiveiodine131therapyindifferentiatedthyroidcancersreviewof19cases AT alasirim nasolacrimalductobstructionfollowingradioactiveiodine131therapyindifferentiatedthyroidcancersreviewof19cases AT tunioma nasolacrimalductobstructionfollowingradioactiveiodine131therapyindifferentiatedthyroidcancersreviewof19cases AT aljohaninj nasolacrimalductobstructionfollowingradioactiveiodine131therapyindifferentiatedthyroidcancersreviewof19cases AT bayoumiy nasolacrimalductobstructionfollowingradioactiveiodine131therapyindifferentiatedthyroidcancersreviewof19cases AT muniri nasolacrimalductobstructionfollowingradioactiveiodine131therapyindifferentiatedthyroidcancersreviewof19cases AT alayoubia nasolacrimalductobstructionfollowingradioactiveiodine131therapyindifferentiatedthyroidcancersreviewof19cases
_version_	1718398374457114624

Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases

Ejemplares similares